Table 1.
Details on anti-MET agents already available in the clinical scenario for anticancer therapy
| Drug | Target | Cancer type | References |
|---|---|---|---|
| Anti-MET monoclonal antibodies | |||
| SAIT301 | MET | Advanced MET positive solid tumors | [30]a |
| ARGX-111 | MET | MET protein overexpressing advanced cancer | [31]a |
| MetMab (ornatuzumab) | MET | Advanced or metastatic solid tumors | [32–37]a |
| JNJ-61186372 | MET-EGFR (bispecific ab) | Advanced NSCLCs | [38–40]a |
| ABT-700 | MET | Advanced solid tumors | |
| MET tyrosine kinase inhibitors | |||
| PF-02341066 (crizotinib) | MEK, ALK, ROS 1 (triple inhibitor) | Advanced NSCLCs, gastric cancers, metastatic urothelial cancers,anaplastic large cell lymphoma, colorectal cancers, advanced relapsed/refractory solid tumors, primary CNS tumors | [41–43]a |
| XL-184 (cabozantinib) | MET, VEGFR2 (dual inhibitor) | NSCLCs with brain metastasis, advanced cholangiocarcinoma, metastatic triple negative breast cancers, colorectal cancers, metastatic Merkel cell carcinoma, recurrent endometrial cancers, breast cancers with brain metastasis, metastatic renal cell carcinoma | [44–54]a |
| AZD6094 (Volitinib) | MET | Gastric adenocarcinoma, papillary renal cell carcinoma | [55–58]a |
| GSK1363089 (Foretinib) | MET, VEGFR2 (dual inhibitor) | Papillary renal cell carcinoma, medulloblastoma, metastatic gastric cancers, hepatocellular carcinoma | [59–67]a |
| AMG337 | MET | Advanced gastric and esophageal adenocarcinoma, advanced solid tumors | [68–72]a |
| ARQ-197 (tivantinib) | MET (non ATP-competitive) | Relapsed/refractory multiple myeloma; locally advancer or metastatic colorectal cancers; metastatic triple negative breast cancers; childhood relapsed/refractory solid tumors; recurrent/metastatic head and neck cancers; gastric cancers; metastatic solid tumors; metastatic prostate cancers; metastatic or locally advancer kidney cancers; mesothelioma; small cell lung cancers; hepatocellular carcinoma; | [73–90]a |
| INC280 (capmatinib) | MET | NSCLCs; CRCs; HNSCC; advanced solid tumors, hepatocellular carcinoma; metastatic CRCs; metastatic renal cell carcinoma; recurrent glioblastoma; advanced or metastatic melanoma | [91, 92]a |
| EMD 1204831 | MET | Advanced solid tumors; advanced hepatocellular carcinoma | [93]a |
| MGCD265 | MEK, ALK (dual inhibitor) | Advanced cancers | [94, 95]a |
| MK8033 | MET, RON (ATP-competitive dual inhibitor) | Advanced solid tumors | [96]a |
| PF-04217903 | MET (ATP-competitive) | Advanced cancers | [97–99]a |
aFor more details see: www.clinicaltrials.gow